Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Diatrizoic acid
Drug ID BADD_D00647
Description A commonly used x-ray contrast medium. As diatrizoate meglumine and as Diatrizoate sodium, it is used for gastrointestinal studies, angiography, and urography.
Indications and Usage Used, alone or in combination, for a wide variety of diagnostic imaging methods, including angiography, urography, cholangiography, computed tomography, hysterosalpingography, and retrograde pyelography. It can be used for imaging the gastrointestinal tract in patients allergic to barium.
Marketing Status approved; vet_approved
ATC Code V08AA01
DrugBank ID DB00271
KEGG ID D02240
MeSH ID D003973
PubChem ID 2140
TTD Drug ID D0T9DT
NDC Product Code Not Available
UNII 5UVC90J1LK
Synonyms Diatrizoate | Benzoic acid, 3,5-bis(acetylamino)-2,4,6-triiodo- | Hypaque | Diatrizoic Acid | Urothrast | Urotrast | Urogranoic Acid | Sodium Diatrizoate | Diatrizoate, Sodium | Diatrizoate Sodium | Sodium-Magnesium Diatrizoate | Diatrizoate, Sodium-Magnesium | Amidotrezoate | Amidotrizoate | Hypaque 50
Chemical Information
Molecular Formula C11H9I3N2O4
CAS Registry Number 117-96-4
SMILES CC(=O)NC1=C(C(=C(C(=C1I)C(=O)O)I)NC(=O)C)I
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Generalised tonic-clonic seizure17.12.01.002--Not Available
Glossitis07.14.01.001--Not Available
Haematoma24.07.01.001--
Haematuria21.10.01.018; 24.07.01.047; 20.02.01.006--
Haemoglobin13.01.05.018--Not Available
Haemoptysis02.11.04.009; 22.02.03.004; 24.07.01.006--Not Available
Headache17.14.01.001--
Hemiplegia17.01.04.002--Not Available
Hyperaemia24.03.02.002--Not Available
Hyperhidrosis08.01.03.028; 23.02.03.004--
Hypersensitivity10.01.03.003--
Hypertension24.08.02.001--
Hypoaesthesia23.03.03.081; 17.02.06.023--Not Available
Hypopnoea22.02.01.021--Not Available
Hypotension24.06.03.002--
Hypoventilation22.02.01.007--Not Available
Infection11.01.08.002--Not Available
Injection site inflammation12.07.03.009; 08.02.03.008--Not Available
Injection site pain12.07.03.011; 08.02.03.010--Not Available
Injury12.01.08.004--Not Available
Instillation site pain12.07.01.008; 08.02.01.008--Not Available
Lacrimation increased06.08.02.004--
Laryngeal oedema23.04.01.005; 22.04.02.001; 10.01.05.003--
Laryngospasm22.04.02.002--
Leukopenia01.02.02.001--Not Available
Lip swelling23.04.01.007; 10.01.05.005; 07.05.04.005--Not Available
Loss of consciousness17.02.04.004--Not Available
Malaria11.06.04.001; 01.03.02.007--Not Available
Muscle spasms15.05.03.004--
Muscle spasticity17.05.03.007; 15.05.04.011--
The 3th Page    First    Pre   3 4 5 6    Next   Last    Total 6 Pages